[go: up one dir, main page]

JP2015083582A5 - - Google Patents

Download PDF

Info

Publication number
JP2015083582A5
JP2015083582A5 JP2014247793A JP2014247793A JP2015083582A5 JP 2015083582 A5 JP2015083582 A5 JP 2015083582A5 JP 2014247793 A JP2014247793 A JP 2014247793A JP 2014247793 A JP2014247793 A JP 2014247793A JP 2015083582 A5 JP2015083582 A5 JP 2015083582A5
Authority
JP
Japan
Prior art keywords
suspension
less
volume
suspension according
gauge needle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014247793A
Other languages
English (en)
Other versions
JP2015083582A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015083582A publication Critical patent/JP2015083582A/ja
Publication of JP2015083582A5 publication Critical patent/JP2015083582A5/ja
Pending legal-status Critical Current

Links

Claims (6)

  1. タンパク質濃度が200mg/mL以上であり、かつ粘度が50センチポアズ未満である、対象への皮下送達に用いるためのタンパク質粒子の懸濁液。
  2. 送達が、21〜27ゲージの針を備える注射器を用いて達成される、請求項1に記載の懸濁液。
  3. 注射器が25〜27ゲージの針を備える、請求項2に記載の懸濁液。
  4. 体積が5mL以下である、請求項1〜3のいずれか1項に記載の懸濁液。
  5. 体積が1.5mL以下である、請求項1〜3のいずれか1項に記載の懸濁液。
  6. タンパク質粒子がサブミクロンサイズの粒子である、請求項1〜5のいずれか1項に記載の懸濁液。
JP2014247793A 2008-11-16 2014-12-08 高濃度の低粘度懸濁液 Pending JP2015083582A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11508008P 2008-11-16 2008-11-16
US61/115,080 2008-11-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011536414A Division JP5711138B2 (ja) 2008-11-16 2009-11-10 高濃度の低粘度懸濁液

Publications (2)

Publication Number Publication Date
JP2015083582A JP2015083582A (ja) 2015-04-30
JP2015083582A5 true JP2015083582A5 (ja) 2015-07-02

Family

ID=42170660

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011536414A Expired - Fee Related JP5711138B2 (ja) 2008-11-16 2009-11-10 高濃度の低粘度懸濁液
JP2014247793A Pending JP2015083582A (ja) 2008-11-16 2014-12-08 高濃度の低粘度懸濁液

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011536414A Expired - Fee Related JP5711138B2 (ja) 2008-11-16 2009-11-10 高濃度の低粘度懸濁液

Country Status (7)

Country Link
US (2) US8779094B2 (ja)
EP (1) EP2376522A4 (ja)
JP (2) JP5711138B2 (ja)
KR (1) KR20110103961A (ja)
CA (1) CA2743789C (ja)
IL (1) IL212919A (ja)
WO (1) WO2010056657A2 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
EP2544721B1 (en) * 2010-03-09 2017-12-06 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9445990B2 (en) * 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
AU2012225277A1 (en) * 2011-03-10 2013-09-26 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CN104023748B (zh) * 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
US9737662B2 (en) 2011-11-07 2017-08-22 Battelle Memorial Institute Processes for delivery of viscous drug therapies
TR201810930T4 (tr) * 2012-05-18 2018-08-27 Genentech Inc Yüksek konsantrasyonlu monoklonal antikor formülasyonları.
US20140342006A1 (en) * 2013-03-15 2014-11-20 Ansun Biopharma, Inc. Methods for Preparing Injectable Protein Microparticle Suspensions
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
CN103976947B (zh) * 2014-06-05 2016-08-17 段明星 一种含酶油悬浮剂及其制备方法与应用
SG11201702614SA (en) * 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
JP5774190B1 (ja) * 2014-12-12 2015-09-09 ジーンメディカル株式会社 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法
EP3231433B1 (en) 2014-12-12 2023-12-27 Motejo. Ltd Agent for hypodermic injection
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
US11654112B2 (en) 2016-11-22 2023-05-23 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
EP3917500A2 (en) 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
AU2020219125A1 (en) 2019-02-05 2021-08-12 Lindy Biosciences, Inc. Isolated cell culture components and methods for isolating the same from liquid cell culture medium
US20200376128A1 (en) * 2019-06-01 2020-12-03 Lupin Holdings B.V. Monodisperse resorbable polyester polymer compositions, systems, and methods
CN114514035A (zh) * 2019-09-13 2022-05-17 伊勒卓菲公司 递送用于治疗疾病的治疗性生物制剂的组合物和方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
SE465950B (sv) 1989-10-23 1991-11-25 Medinvent Sa Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
WO1993020134A1 (en) 1992-03-30 1993-10-14 Alza Corporation Additives for bioerodible polymers to regulate degradation
ZA932272B (en) 1992-03-30 1993-10-19 Alza Corp Viscous suspensions of controlled-release drug particles
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
DE69431533T2 (de) 1994-06-13 2003-10-02 Alza Corp., Palo Alto Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
EP0909175B1 (en) 1996-07-03 2003-06-04 Alza Corporation Non-aqueous protic peptide formulations
IN184589B (ja) 1996-10-16 2000-09-09 Alza Corp
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
EP1152749B1 (en) 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
WO2002067991A1 (en) * 2001-02-23 2002-09-06 Genentech, Inc. Erodible polymers for injection
NZ530700A (en) * 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
JP2006514954A (ja) 2002-12-31 2006-05-18 ネクター セラピューティクス 抗体含有粒子及び組成物
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
AU2004249172A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US20050142201A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for fabrication, uses and compositions of small spherical particles of hGH prepared by controlled phase separation
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112893A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070015689A1 (en) 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US7651770B2 (en) 2005-12-16 2010-01-26 The University Of Kansas Nanoclusters for delivery of therapeutics
WO2007072982A1 (en) 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CN101081882A (zh) * 2007-07-06 2007-12-05 天津大学 大分子印迹交联聚乙烯基吡咯烷酮微球及低温悬浮聚合制备方法
JP2009173610A (ja) 2008-01-28 2009-08-06 Fujifilm Corp タンパク質ナノ粒子
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
EP2285825B1 (en) 2008-05-09 2020-07-15 South Dakota State University Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
US20100009007A1 (en) 2008-07-10 2010-01-14 Baxter International Inc. Non-covalent modification of microparticles and process of preparing same
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado

Similar Documents

Publication Publication Date Title
JP2015083582A5 (ja)
AR099912A1 (es) Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
IL274398A (en) ANTI-IGF-1R antibodies that eliminate binding to FCRN and their use in the treatment of vascular diseases of the eye
TWD190432S (zh) 鼻管
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
MX381016B (es) Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
JP2016540026A5 (ja)
JP2016540030A5 (ja)
BR112016016932A8 (pt) uso de uma combinação de oxaliplatina (oxa), leucovorina (lv) e 5-fluorouracil (5-fu)
EP3037877A3 (en) A pellicle
IL269962A (en) Material for production containing anesthetic, buffer and glycosaminoglycan in a syringe with improved stability
TWD174176S (zh) 給藥裝置之部分(二)
ES2700448R1 (es) Uso de ligandos del receptor sigma en la diabetes y el sindrome metabolico
RU2014151103A (ru) Применение соединений класса 1,3,4-тиадиазина и их фармацевтической композиции с аскорбиновой кислотой в качестве средства коррекции экспериментального аллоксанового сахарного диабета
Sklar et al. Collapse Box From the Editor
נסים ליאון Politics of Memory-The Israeli Underground's Struggle for Inclusion in the National Pantheon and Military Commemoralization
Yan Mobile Internet Era’s Explosive Growth in Full Swing
JP2013505038A5 (ja)
CN302510909S (zh) 燃油喷射泵(cb6p990)
METROPOLIS THE SOCIAL AND THE NATIONAL QUESTION IN THE EASTERN METROPOLIS
CN302586572S (zh) 无针注射器
CN302570718S (zh) 医用敷料
吴一凡 My Chinese Teacher
潘禹潼 My Bedroom